Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), today announced the outcome of the U.S. Food and Drug Administration ("FDA") Cardiovascular and Renal Drugs Advisory Committee ("Committee") meeting on bardoxolone methyl ("bar